MedTrace Logo

Examining the Effects of Mitochondrial Oxidative Stress in DCM

NCT05410873 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-09-18

No results posted yet for this study

Summary

Double blind, randomised, placebo-controlled trial of MitoQ (mitoquinol mesylate) in 106 patients with dilated cardiomyopathy, examining the effect of reducing mitochondrial oxidative stress on myocardial energetics and myocardial function using 31-phosphorus magnetic resonance spectroscopy and cardiovascular magnetic resonance.

Conditions

  • Dilated Cardiomyopathy

Interventions

DRUG

MitoQ Compound

Mitoquinol mesylate

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Brian Halliday, MBChB PhD · Imperial College London and Royal Brompton Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-26
Primary Completion
2024-06-19
Completion
2024-06-19

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05410873 on ClinicalTrials.gov